Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04627116
Recruitment Status : Enrolling by invitation
First Posted : November 13, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
The subjects will be admitted to the Phase I Clinical Research Center on day -1. Subjects received once-daily doses of Tecarfarin for up to 14 days.Subjects can leave the Phase I Clinical Research Center on the day 21.And returned to the research center for follow-up on the day 28 and 35.

Condition or disease Intervention/treatment Phase
Healthy Chinese Volunteers Drug: Tecarfarin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Multiple-Dose, Safety and Tolerability、PK/PD Study of Tecarfarin in Healthy Chinese Volunteers
Actual Study Start Date : April 19, 2020
Estimated Primary Completion Date : December 5, 2020
Estimated Study Completion Date : December 30, 2020

Arm Intervention/treatment
Experimental: Tecarfarin 10mg Drug: Tecarfarin
Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.

Experimental: Tecarfarin 20mg Drug: Tecarfarin
Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.

Experimental: Tecarfarin 30mg Drug: Tecarfarin
Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.

Experimental: Tecarfarin 40mg Drug: Tecarfarin
Ten (10) healthy Chinese subjects received once-daily doses of Tecarfarin on fasting every morning for 14 days.




Primary Outcome Measures :
  1. The primary objective of this study was to evaluate the safety and tolerability of Tecarfarin when administered as rising multiple oral doses to healthy Chinese volunteers. [ Time Frame: doses of Tecarfarin for up to 14 days. ]
    Subjects received once-daily doses of Tecarfarin for up to 14 days.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

1) the subjects were fully aware of the purpose, nature, methods and possible adverse reactions of the trial, voluntarily act as subjects, and sign an informed consent form before the commencement of any research process.

2)Healthy volunteers between the ages of 18 to 50 years old (inclusive). 3)Weight: male ≥ 50.0kg, female ≥ 45.0kg; Body Mass Index (BMI) ≥19 and ≤ 24 kg/m2.

4) The physical examination, vital sign measurements, clinical laboratory assessments hematology, clinical chemistry, or urinalysis, etc.) and 12-lead ECG were judged normal, or abnormal without clinical significance by the investigators.

Exclusion Criteria:

1. Positive test results for HIV, syphilis antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV Ab) at Screening.

2) Dysphagia or documented history of any gastrointestinal disorders that affect drug absorption.

3) Subjects with difficulty in venipuncture, those who cannot tolerate venipuncture, and those who have a history of needlesickness and bloodsickness.

4) Positive tests for urine drugs of abuse at Screening or a history of drug or alcohol abuse/dependence.

5) Use of tobacco products 3 months before screening. 6)Heavy tea, coffee and / or caffeinated drinks (more than 8 cups, 1 cup = 250 mL) drinker per day within 3 months prior to screening.

7)Subjects who drunk frequently within 6 months prior to screening (intake of more than 14 units of alcohol per week. A unit is 360 mL beer, 45 mL of 40% liquor or 150 mL wine).

8)Any out-of-normal-range PT, aPTT, TT, FIB,INR, protein C, protein S or coagulation factors II, VII, X at screening.

9)History of cardiovascular, renal, pulmonary, nervous system, liver and/or endocrine disease.

10)Documented history of bleeding diathesis, coagulopathy, or inherited disorders of coagulation.

11)Evidence of active bleeding, including but not limited to gastrointestinal bleeding (hematemesis, hematochezia, positive fecal occult blood), urinary tract bleeding, mucosal bleeding (gingival, epistaxis) and unexplained subcutaneous bleeding or ecchymosis.

12)Participation in a previous clinical trial within 3 months prior to Screening.

13)Clinically significant surgical procedure within 4 weeks prior to Screening or planned to undergo surgery during the study period.

14) Clinically significant blood loss or blood donation > 550 ml within 3 months prior to Screening.

15)Taking any medication 14 days prior to Screening. 16)Known allergy or hypersensitivity to warfarin or the investigational product.

17)Pregnancy or Lactation. 18)Female subjects cannot avoid menstruation during administration. 19)subjects of childbearing age are not guaranteed to have no fertility plan, sperm donation, egg donation plan and voluntary use of non-drug contraceptive measures (including subcutaneous injection of contraceptive, contraceptive injections, subcutaneous implantation of contraceptives, local contraceptives such as spermicide, etc.) from two weeks before screening to 6 months after the end of the trial.

20)Investigator would make the subject unsuitable for the study or put them at additional risks.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04627116


Locations
Layout table for location information
China
The Second Hospital of Anhui Medical University
Hefei, China
Sponsors and Collaborators
Lee's Pharmaceutical Limited
Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited
ClinicalTrials.gov Identifier: NCT04627116    
Other Study ID Numbers: ZK-TEK-201905
First Posted: November 13, 2020    Key Record Dates
Last Update Posted: November 13, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No